Top 100 Most Prescribed, Top Selling Drugs

The hypothyroid medication levothyroxine (Synthroid, AbbVie) continues to be the nation’s most prescribed drug, and the antipsychotic aripiprazole (Abilify, Otsuka Pharmaceutical) continues to have the highest sales, at nearly $6.9 billion, according to the latest data from research firm IMS Health.

The data reflect a rolling 12 months of history (April 2013 – March 2014) on the top 100 drugs by total sales and total prescriptions in the United States.

Following levothyroxine (with just more than 23 million prescriptions) as most prescribed drug in the United States were the cholesterol-lowering drug rosuvastatin (Crestor, AstraZeneca), at about 22.9 million; the proton pump inhibitor esomeprazole (Nexium, AstraZeneca), at roughly 19.3 million; the asthma medication albuterol (Ventolin HFA, GlaxoSmithKline), at about 17.5 million; and the chronic obstructive pulmonary disease medication fluticasone/salmeterol (Advair Diskus, GlaxoSmithKline), at more than 15.5 million

 The hypothyroid medication levothyroxine (Synthroid, AbbVie) continues to be the nation’s most prescribed drug, and the antipsychotic aripiprazole (Abilify, Otsuka Pharmaceutical) continues to have the highest sales, at nearly $6.9 billion, according to the latest data from research firm IMS Health.

The data reflect a rolling 12 months of history (April 2013 – March 2014) on the top 100 drugs by total sales and total prescriptions in the United States.

Following levothyroxine (with just more than 23 million prescriptions) as most prescribed drug in the United States were the cholesterol-lowering drug rosuvastatin (Crestor, AstraZeneca), at about 22.9 million; the proton pump inhibitor esomeprazole (Nexium, AstraZeneca), at roughly 19.3 million; the asthma medication albuterol (Ventolin HFA, GlaxoSmithKline), at about 17.5 million; and the chronic obstructive pulmonary disease medication fluticasone/salmeterol (Advair Diskus, GlaxoSmithKline), at more than 15.5 million.

Rounding out the top 10 most prescribed drugs for the period were the antidepressant duloxetine (Cymbalta, Eli Lilly), the antihypertensive valsartan (Diovan, Novartis), the attention deficit drug lisdexamfetamine dimesylate (Vyvanse, Shire), insulin glargine injection (Lantus Solostar, sanofi-aventis), and the antiepileptic pregabalin (Lyrica, Pfizer).

After aripiprazole, the next best selling drugs for the period April 2013 through March 2014 were esomeprazole magnesium (Nexium, AstraZeneca) at nearly $6.3 billion, and the arthritis drug adalimumab (Humira, AbbVie), at $5.9 billion.

Rounding out the top 10 in sales were Crestor ($5.5 billion), Advair Diskus ($5.1 billion), the arthritis drugs etanercept (Enbrel, Amgen; almost $4.9 billion) and infliximab (Remicade, Centocor; $4.2 billion), Cymbalta ($4.1 billion), the multiple sclerosis drug glatiramer acetate (Copaxone, Teva Pharm; almost $3.7 billion), and the neutropenia drug pegfilgrastim (Neulasta, Amgen; $3.6 billion).

17-May-2014